All In Biotech

Drug Trial Radar · NCT05033886

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) and Considered Unsuitable for Hormone Replacement Therapy

Last checked: Nov 20, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 453 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

453

Actual

Start

Nov 8, 2021

Primary completion

Mar 27, 2023

Study completion Apr 20, 2023

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Sep 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is for women in menopause who have moderate to severe hot flashes. It is for women who are unable to use hormone replacement therapy (HRT). Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause. They can disrupt a woman's daily life. The study medicines (also called investigational products, or IP) are tablets of fezolinetant or placebo. An investigational product means that the product is not yet licensed. In this study, a placebo is a dummy treatment that looks like fezolinetant but does not have any medicine in it. The study will compare fezolinetant with the placebo to learn if fezolinetant reduces the number and severity of hot flashes. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. In the last 10 days before their next clinic visit, the women will record information about their hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. Women will be picked for 1 of 2 treatments (fezolinetant or placebo) by chance alone. Women who take part in the study will take 2 tablets every day for 24 weeks. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study medicines (fezolinetant or placebo). The women will continue recording information about their hot flashes on the electronic device or their phone. They will also use another device to answer questions about how hot flashes affect their daily life. During the study, the women will visit their study clinic several times for a check-up. This will happen during Weeks 2, 4, 8, 12, 16, 20, 24, and 27. Some women may be able to have home visits instead, from Week 2 to Week 20. At the check-up, they will be asked if they have any medical problems. Other checks will include vital signs (heart rate, temperature and blood pressure) and some blood samples taken for laboratory tests. At some check-ups, the women will have a physical exam. In Week 2 and Week 24, the women will have an ECG to check their heart rhythm. Women who have a uterus will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs. The last check-up (at Week 27) will be 3 weeks after they take their last tablets of study medicine (fezolinetant or placebo).

Conditions

  • Vasomotor Symptoms

Interventions

  • fezolinetantDrug

    oral

  • placeboDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in the frequency of moderate to severe VMS from baseline at week 24Time frame: Baseline, week 24

Locations

69 sites in 16 countries. Site status is shown where the registry gives one.

  • Site BE32005

    Tienen, Vlaams Brabant, Belgium

  • Site CA15002

    Québec, Canada

  • Site CA15009

    Québec, Canada

  • Site CA15007

    Québec, Canada

  • Site CA15008

    Brampton, Ontario, Canada

  • Site CA15010

    London, Ontario, Canada

  • Site CA15003

    Sarnia, Ontario, Canada

  • Site CA15012

    Montreal, Quebec, Canada

  • Site CA15014

    Québec, Quebec, Canada

  • Site CA15011

    Saint Charles Borromeee, Quebec, Canada

  • Site CA15001

    Sherbrooke, Quebec, Canada

  • Site CA15005

    Victoriaville, Quebec, Canada

  • Site CZ42008

    Brno, Czechia

  • Site CZ42010

    České Budějovice, Czechia

  • Site CZ42005

    Cheb, Czechia

  • Site CZ42009

    Hradec Králové, Czechia

  • Site CZ42011

    Náchod, Czechia

  • Site CZ42003

    Olomouc, Czechia

  • Site CZ42004

    Písek, Czechia

  • Site CZ42006

    Prague, Czechia

  • Site CZ42007

    Tábor, South Bohemian Region, Czechia

  • Site CZ42002

    Vodňany, South Bohemian Region, Czechia

  • Site DK45005

    Arhus C, Denmark

  • Site DK45003

    Gandrup, North Denmark, Denmark

  • Site DK45002

    Odense, Region Syddanmark, Denmark

  • Site DK45004

    Vejle, Region Syddanmark, Denmark

  • Site FI35801

    Kuopio, Finland

  • Site FI35803

    Oulu, Finland

  • Site FR33003

    La Rochelle, France

  • Site FR33001

    Nantes, France

  • Site DE49004

    Hamburg, Germany

  • Site DE49005

    Hamburg, Germany

  • Site DE49002

    Leipzig, Germany

  • Site DE49008

    Muechen, Germany

  • Site DE49006

    Schwerin, Germany

  • Site HU36002

    Debrecen, Hungary

  • Site HU36004

    Kecskemét, Hungary

  • Site HU36001

    Szekesfeherver, Hungary

  • Site IT39002

    Bologna, Italy

  • Site IT39006

    Pavia, Italy

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.